Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234756 | 0.93 | FPR1 (0.47) | FPR1TSHRRXFP1TP53TRPA1 | |
| SCHEMBL8227862 | 0.89 | AVPR2 (0.41) | RXFP1 | |
| SCHEMBL8233136 | 0.88 | KMT2A (0.47) | KMT2ATDP1HDAC6RAB9ATP53 | |
| SCHEMBL8227826 | 0.87 | AVPR2 (0.48) | CNR1RXFP1TRPA1 | |
| SCHEMBL8227821 | 0.85 | LMNA (0.51) | KMT2ATSHRTP53MAPT | |
| SCHEMBL4512923 | 0.84 | CNR1 (0.47) | CNR1TRPA1MAPT | |
| SCHEMBL8227891 | 0.83 | TP53 (0.51) | KMT2ATP53TRPA1MAPT | |
| SCHEMBL12057100 | 0.83 | TRPA1 (0.44) | KMT2ARXFP1TP53TRPA1MAPT | |
| Bicarbonate SCHEMBL16530565 | 0.83 | KDM4E (0.47) | KMT2AFPR1TDP1TSHRTP53 | |
| SCHEMBL8234693 | 0.82 | TP53 (0.55) | KMT2ATP53TRPA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | CNR1 282/4885KMT2A 4657/4885FPR1 1111/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | CNR1 282/4885KMT2A 4657/4885FPR1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.